SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 52.51+2.7%Nov 14 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (76)3/17/1999 1:54:00 PM
From: jeffbas  Read Replies (1) of 52153
 
Richard, has anyone every tried to create a valuation model of stocks
based on market cap to existing drug sales or, perhaps better, gross margin dollars from existing drug sales, capitalized at some multiple. I do not know if it would be feasible but it would seem that is a first step basis of the value of what the company now has, and you would see what you are really paying for the balance of the pipeline.
Would something like that be helpful in comparing the bigger ones
with the ones with no drugs on the market?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News